Last reviewed · How we verify
NCT06576167
COVID-19 Self-testing IMPROVE
NA trial testing IMPROVE in COVID-19 in 1,271 participants. Completed in 2 December 2024.
2 December 2024
Quick facts
| Lead sponsor | Temple University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 1,271 |
| Start date | 15 June 2023 |
| Primary completion | 2 December 2024 |
| Estimated completion | 2 December 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- IMPROVE
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Temple University
Who can join
18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study aims to engage community partners to implement IMPROVE intervention and promote (COVID-19) rapid testing among vulnerable Asian Americans in the Greater Philadelphia Area and New York City
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06576167
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of IMPROVE
Trials testing the same drug.
- NCT06885320 — Building Undergraduate Coping & Knowledge for Stress-Resilience · NA · completed
- NCT06299657 — Intervention for Managing Physical Reactions to Overwhelming Emotions · NA · completed
- NCT04598958 — A Multidisciplinary "Integrated Management Team to Improve Maternal-Child Outcomes (IMPROVE)" Intervention to Improve Ma · NA · completed
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Temple University trials
Trials by the same sponsor.
- NCT07055360 — A Trauma-Informed Intervention for the Newly HIV-Diagnosed · NA · not yet recruiting
- NCT07277816 — Photo-experiencing and Reflective Listening (PEARL) to Promote Healing Engagement for Survivors of Violence · NA · recruiting
- NCT07151768 — Prospective Validation of the Novel PVD-B65 Risk Score in Patients With Chronic Lung Disease and Pulmonary Hypertension · recruiting
- NCT07027865 — Sip and Snack Better (SSB) Study: Improving Added Sugar in Adolescents · NA · active not recruiting
- NCT06810557 — Brief Behavioral Sleep Intervention for Obesity Prevention in Primary Care · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06576167 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Temple University
- Last refreshed: 10 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06576167.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing